SOTIO is a biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy based on dendritic cells. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also collaborating with NBE-Therapeutics on the development of novel antibody-drug conjugate products (ADC), with LDC and the Max Planck Society on an oncology program addressing a novel target in tumor metabolism and with Cytune Pharma on developing novel IL15-based immunotherapies for the treatment of cancer. Phase I/Ib clinical trial with IL-15 superagonist SO-C101 was initiated in 2019. SOTIO has facilities in Europe, the United States, China and Russia.